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Abstract
 
Using intravital microscopy, we examined the role played by B
 
1
 
 receptors in leukocyte traffick-
ing across mouse mesenteric postcapillary venules in vivo. B
 
1
 
 receptor blockade attenuated in-
terleukin (IL)-1
 
b
 
–induced (5 ng intraperitoneally, 2 h) leukocyte–endothelial cell interactions
and leukocyte emigration (
 
z
 
50% reduction). The B
 
1
 
 receptor agonist des-Arg
 
9
 
bradykinin
(DABK), although inactive in saline- or IL-8–treated mice, caused marked neutrophil rolling,
adhesion, and emigration 24 h after challenge with IL-1
 
b
 
 (when the cellular response to IL-1
 
b
 
had subsided). Reverse transcriptase polymerase chain reaction and Western blot revealed a
temporal association between the DABK-induced response and upregulation of mesenteric B
 
1
 
receptor mRNA and de novo protein expression after IL-1
 
b
 
 treatment. DABK-induced leu-
kocyte trafficking was antagonized by the B
 
1
 
 receptor antagonist des-arg
 
10
 
HOE 140 but not by
the B
 
2
 
 receptor antagonist HOE 140. Similarly, DABK effects were maintained in B
 
2
 
 receptor
knockout mice. The DABK-induced responses involved the release of neuropeptides from C
fibers, as capsaicin treatment inhibited the responses. Treatment with the neurokinin (NK)
 
1
 
and NK
 
3
 
 receptor antagonists attenuated the responses, whereas NK
 
2
 
, calcitonin gene-related
peptide, or platelet-activating factor receptor antagonists had no effect. Substance P
 
 
 
caused leu-
kocyte recruitment that, similar to DABK, was inhibited by NK
 
1
 
 and NK
 
3
 
 receptor blockade.
Mast cell depletion using compound 48/80 reduced DABK-induced leukocyte trafficking, and
DABK treatment was shown histologically to induce mast cell degranulation. DABK-induced
trafficking was inhibited by histamine H
 
1
 
 receptor blockade. Our findings provide clear evi-
dence that B
 
1
 
 receptors play an important role in the mediation of leukocyte–endothelial cell
interactions in postcapillary venules, leading to leukocyte recruitment during an inflammatory
response. This involves activation of C fibers and mast cells, release of substance P
 
 
 
and hista-
mine, and stimulation of NK
 
1
 
, NK
 
3
 
, and H
 
1
 
 receptors.
Key words: kinin B
 
1
 
 receptor • leukocyte–endothelial cell interaction • intravital microscopy • 
C ﬁber • mast cell
 
Introduction
 
The kinins, specifically bradykinin (BK)
 
1
 
 and its biologically
active metabolite des-Arg
 
9
 
bradykinin (DABK), are produced
at sites of inflammation and are important inflammatory me-
diators (1). The effects of these kinins are brought about by
interaction with specific G protein–coupled receptors, of
which there are two clearly defined and cloned types: B
 
1
 
 and
B
 
2
 
 (2). BK produces its acute proinflammatory effects via the
activation of constitutively expressed B
 
2
 
 receptors. The ac-
 
tion of BK is characterized by
 
 
 
increased blood flow and vas-
cular permeablitity (2, 3). The effects of DABK, in contrast,
are mediated by B
 
1
 
 receptors. B
 
1
 
 receptors are not normally
expressed, but are induced selectively during the host inflam-
matory response. Activation of B
 
1
 
 receptor by its endoge-
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1
 
Abbreviations used in this paper:
 
 BK2r
 
2
 
/
 
2
 
, B
 
2
 
 receptor knockout mice;
BK, bradykinin; CGRP, calcitonin gene-related peptide; DABK, des-
Arg
 
9
 
bradykinin; ECL, enhanced chemiluminescence; NK, neurokinin;
PAF, platelet-activating factor; PBS-T, 0.1% Tween-20 in PBS; RT, re-
verse transcriptase; 
 
V
 
WBC
 
, white blood cell velocity. 
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nous ligand (DABK in rodents and Lys-DABK in humans)
produces a proinflammatory profile similar to that of B
 
2
 
 re-
ceptor activation, but is also characterized by a stimulation of
inflammatory cell accumulation (4). B
 
1
 
 receptors, similar to
other proinflammatory proteins induced during inflamma-
tion (such as cyclooxygenase [COX]-2 and inducible nitric
oxide synthase [iNOS]), are induced by certain immuno-
stimulants, including IL-1
 
b
 
 (4). For this reason, the kinin B
 
1
 
receptor may be an innovative target in the development of
novel antiinflammatory strategies.
Knowledge of the contribution of B
 
1
 
 receptors to the reg-
ulation of the inflammatory process may be important, as B
 
2
 
receptors undergo rapid agonist-induced desensitization (5), a
process possibly linked to B
 
1
 
 receptor induction (6), and are
unlikely to be involved in subacute and chronic inflammatory
conditions (1). In contrast, B
 
1
 
 receptors, once induced, do
not undergo agonist-induced desensitization to any apprecia-
ble extent (5) and are better equipped to mediate the devel-
opment and progression of a chronic inflammatory response.
It has therefore been proposed that an integrated system de-
velops from B
 
2
 
 receptor–mediated acute inflammation to a
sustained B
 
1
 
 receptor–mediated chronic inflammation, the
latter mainly characterized by cellular infiltration (1).
Previous studies using models of experimental inflamma-
tion have shown that B
 
1
 
 receptor activation plays a role in
the process of neutrophil accumulation (7–9). However, the
step(s) activated by B
 
1
 
 receptors in the promotion of neutro-
phil extravasation have not been investigated, and it is not
known whether B
 
1
 
 receptor activation can trigger leukocyte
interactions with the endothelium of postcapillary venules.
Intravital microscopy techniques have been used over the
past 10 years to elucidate the mechanisms involved in leuko-
cyte accumulation (10). Upon application of an inflamma-
tory stimulus, neutrophils roll on the endothelium of in-
flamed postcapillary venules, an action mediated by selectins
CD62P, CD62E, or CD62L (11). During this phase, the
neutrophil can be activated by various inflammatory media-
tors, such as substance P, and become firmly adherent (12).
This phenomenon is mediated by integrin activation and in-
creased avidity for their counterligands (12). After adhesion,
leukocytes undergo cytoskeletal reorganization leading to
the actual emigration process known as diapedesis.
This study was designed to investigate the cellular and mo-
lecular mechanism(s) by which B
 
1
 
 receptor activation pro-
duces neutrophil accumulation in vivo. To achieve this we
have used (a) a method of observation that accurately quanti-
fies the interaction between the circulating leukocyte and the
endothelium of inflamed postcapillary venules, and (b) corre-
lated this with kinin B
 
1
 
 receptor mRNA and protein expres-
sion. We have also investigated the mechanisms involved
with appropriate histological techniques and via the use of se-
lective agents to inhibit possible intermediary pathways.
 
Materials and Methods
 
Animals.
 
Male Swiss albino mice (10–15 g) were purchased
from Banton and Kingsman and maintained on a standard chow
pellet diet with tap water ad libitum. Animals were housed in
 
groups of eight per cage in a room with controlled lighting (lights
on 8:00–20:00) in which the temperature was maintained at 21–
23
 
8
 
C, and the animals were used 3–4 d after their arrival. Animal
work was performed according to Home Office regulations.
Guidance on the operation on animals was from the Scientific
Procedures Act (1986).
 
Intravital Microscopic Studies.
 
Mice were anesthetized with di-
azepam (60 mg/kg subcutaneously) and Hypnorm
 
®
 
 (0.7 mg/kg
fentanyl citrate and 20 mg/kg fluanisone intramuscularly). Cau-
tery incisions were made along the abdominal region, and the
mesenteric vascular bed was exteriorized and placed on a viewing
Plexiglas stage. The preparation was mounted on a Zeiss Ax-
ioskop FS with a water immersion objective lens (magnification:
 
3
 
40; Zeiss), and an eyepiece (magnification: 
 
3
 
10; Zeiss) was
used to observe the microcirculation. The preparation was trans-
illuminated with a 12-V, 100-W halogen light source. A Hitachi
charge-coupled device color camera (model KPC571) acquired
images that were displayed onto a Sony Trinitron color video
monitor (model PVM 1440QM) and recorded on a Sony super-
VHS video cassette recorder (model SVO-9500 MDP) for subse-
quent offline analysis. A video time-date generator (FOR.A
video timer; model VTG-33) projected the time, date, and stop-
watch function onto the monitor. Mesenteries were superfused
with bicarbonate-buffered solution at 37
 
8
 
C (g/liter: NaCl, 7.71;
KCl, 0.25; MgSO
 
4
 
, 0.14; NaHCO
 
3
 
, 1.51; and CaCl
 
2
 
, 0.22 [pH
7.4], gassed with 5% CO
 
2
 
/95% N
 
2
 
) at a rate of 2 ml/min. The
temperature of the stage was maintained at 37
 
8
 
C. This procedure
has no effect on rectal temperature or blood pressure (our unpub-
lished observations). RBC velocity was measured in venules by
using an optical doppler velocimeter (Microcirculation Research
Institute, Texas A&M University). Venular blood flow was cal-
culated from the product of mean RBC velocity (
 
V
 
mean
 
 
 
5 
 
center-
line velocity/1.6) and microvascular cross-sectional area, assum-
ing a cylindrical geometry. Wall shear rate was calculated by the
Newtonian definition: shear rate 
 
5 
 
8,000
 
3 
 
(
 
V
 
mean
 
/diameter)
(13). One to three randomly selected postcapillary venules (diam-
eter between 20 and 40 
 
m
 
m; length of at least 100 
 
m
 
m) were ob-
served for each mouse
 
Analysis of the Inflammatory Response Elicited by IL-1
 
b
 
.
 
Mu-
rine recombinant IL-1
 
b
 
 (gift from Dr. R.C. Newton, Dupont
Life Sciences Enterprise, Wilmington, DE) was used to induce
neutrophil rolling, adhesion, and emigration. Adapting a protocol
successfully used for the rat mesentery (14, 15), mice received ei-
ther IL-1
 
b
 
 (5 ng intraperitoneally in 0.25 ml of sterile saline) or
vehicle alone, and the mesenteric vascular bed was prepared for
microscopic observation 2 or 24 h later, as described previously
(16). The extent of the inflammatory response elicited by IL-1
 
b
 
was analyzed by measuring white blood cell velocity (
 
V
 
WBC
 
) in
mm/s. Cell adhesion was quantified by counting, for each vessel,
the number of adherent neutrophils in a 100-
 
m
 
m length (see Fig.
1). Leukocyte emigration from the microcirculation into the tis-
sue was quantified by counting the number of cells that had emi-
grated up to 50 
 
m
 
m away from the wall of the 100-
 
m
 
m vessel seg-
ments (see Fig. 1).
 
Assessment of the Involvement of B
 
1
 
 Receptors.
 
The involvement
of B
 
1
 
 receptors in the cellular response to IL-1
 
b
 
 was evaluated
using the selective B
 
1
 
 receptor antagonist des-arg
 
10
 
HOE 140
(
 
d
 
-Arg-[Hyp3,Thi5,
 
d
 
-Tic7,Oic8]-BK, 25 nmol intraperito-
neally; gift from Dr. Gillian Burgess, Novartis Institute for Medi-
cal Sciences, London, UK), which was coinjected with IL-1
 
b
 
.
Neutrophil accumulation was quantified at the 2-h time point.
 
Analysis of the Inflammatory Response Elicited by DABK.
 
To
determine whether activation of B
 
1
 
 receptors by itself led to neu- 
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trophil accumulation, the effect of DABK (Bachem) given 24 h
after IL-1
 
b
 
 (5 ng) was also tested. In this set of experiments, mice
received DABK (10–30 nmol; reference 7), and the cellular re-
sponse assessed 2 or 4 h later by videomicroscopy. Two types of
controls were used for each experiment: one group of animals
was pretreated with sterile saline (0.25 ml) in place of IL-1
 
b
 
 24 h
before DABK, and another group received sterile saline (0.25 ml)
instead of DABK 24 h after IL-1
 
b
 
 injection. The specificity of
IL-1
 
b
 
 pretreatment was controlled for by administering the neu-
trophil activator human rIL-8 (0.5 
 
m
 
g; from the National Insti-
tute of Biological Standards and Controls, South Mimms, UK).
 
Histology.
 
Histological studies were carried out to identify
general histological structures, to enable clear identification of
polymorphonuclear and mononuclear cells, and to visualize me-
senteric mast cells. After saline perfusion through the heart, whole
mount sections of mesentery were prepared on microscope slides
and fixed in 4% paraformaldehyde overnight. General structures
were identified by staining with hematoxylin and eosin to enable
identification of polymorphonuclear and mononuclear cells. For
mast cell identification, sections were fixed in 2% paraformalde-
hyde/2% glutaraldehyde overnight and stained with toluidine
blue (which elicits a metachromatic reaction only in the granules
of mast cells and basophils) as described previously (17). The
number of mast cells were counted for six different fields per sam-
ple with a high powered objective (magnification: 
 
3
 
40). Cells in
a 100-
 
m
 
m
 
2
 
 area were counted. The proportion of mast cells that
were degranulated was expressed as a percentage of the total
number of mast cells.
 
B
 
1
 
 Receptor Gene Expression in Inflamed Mesenteries.
 
polyA1
mRNA was extracted (Micro-FastTrack Kit; Invitrogen) from
homogenates of mesentery, stored at 2708C, from IL-1b– (5 ng,
24 h) and saline-treated mice. polyA1 mRNA was resuspended in
20 ml of Tris (pH 7.5), and 2-ml aliquots were reverse transcribed
in a 20-ml reaction mixture containing 150 ng of random hexanu-
cleotides, 2 mM dNTPs, 50 mM Tris-HCl (pH 8.3), 75 mM
KCl, 3 mM MgCl2, 10 mM dithiothreitol, and 200 U SuperScript
II RNAse H2 reverse transcriptase (RT; Life Technologies).
PCR experiments were performed with 2 ml of the first-strand
DNA in a 25-ml reaction mixture containing 200 mM dNTPs,
1.5 mM MgCl2, 25 pmol of specific forward and reverse primers,
and 1 U of recombinant Taq DNA polymerase (Life Technolo-
gies), and were amplified for 30 cycles with a Biometra-TRIO
thermocycler at 958C for 1 min, 608C for 2 min, and 728C for 2
min, followed by a final extension step at 728C for 10 min.
Mouse B1 receptor cDNA was amplified with the sense primer
(59-GCGGAAATCTACCTGGCTAACTTG-39) at base posi-
tion 392–415 and antisense primer (59-CAGTCACGGGGAG-
GAGGAAACC-39) at base position 806–827 of rat B1 receptor
cDNA (18), which are conserved sequences in the mouse B1 re-
ceptor cDNA (19). The quality of RNA samples was evaluated
by RT-PCR using glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)-specific primers (sense primer, 59-AAGGTGAAG-
GTCGGAGTCAACG-39 [position 8–29] and antisense primer
59-GGCAGAGATGATGACCCTTTTGGC-39 [position 362–
339]). A plasmid containing the mouse B1 receptor cDNA (19)
was used as the template for the positive PCR control reaction.
PCR products were detected by electrophoresis on 2% agarose
gels stained with ethidium bromide.
In some experiments, 4 ml of first-strand cDNA was transferred
to a separate tube, and six serial 1:2 dilutions were made before
PCR amplification using the above conditions. Product intensity
was determined using densitometry, and log plots of starting
amount of cDNA versus product intensity were constructed.
B1 Receptor Protein Expression in Inflamed Mesenteries. Mice re-
ceived either IL-1b (5 ng intraperitoneally) or saline alone,
and 24 h later, the mesenteric vascular bed was rapidly ex-
cised and frozen in liquid nitrogen. Samples were crushed on dry
ice and lysed in ice-cold lysis buffer (20 mM Tris-HCl [pH 7.4],
50 mM NaCl, 50 mM NaF, 5 mM EDTA, and 20 mM
Na4P2O7?10H2O). Lysates were vortexed and centrifuged for 15
min at 25,000 rpm and 48C. The protein concentration of the su-
pernatant was determined using Coomassie brilliant blue with
BSA as the standard. Western blot analysis was performed as fol-
lows: after addition of an equal volume of SDS-PAGE sample
buffer (20 mM Tris-HCl [pH 6.8], 2% SDS [wt/vol], 20% glyc-
erol [vol/vol], 0.025% bromophenol blue [wt/vol], and 10%
2-ME [vol/vol]), the lysates were heated for 3 min at 1008C. Ly-
sates containing equal amounts of protein (20 mg) were separated
on a 12% polyacrylamide gel (wt/vol) followed by electrotransfer
to enhanced chemiluminescence (ECL) nitrocellulose membrane
(Immobilon-P; Millipore). The membrane was blocked by in-
cubation for 60 min in 5% nonfat dry milk and 0.1% Tween-20
in PBS (PBS-T), washed twice with PBS-T, and incubated with
B1 receptor antipeptide antibody (termed A15C [20]; dilution
Table I. Effect of IL-1b on Leukocyte–Endothelial Interactions In Vivo: Assessment of the Role of B1 Receptors
Treatment (time) VWBC* Adherent PMNs‡ Emigrated PMNs§
(mm/s)
Saline (2 h) 54.9 6 6.9 (n 510) 1.3 6 0.4 (n 510) 0.2 6 0.1 (n 510)
IL-1b (2 h) 9.1 6 2.1 (n 5 6)i 11.4 6 1.4 (n 5 6)i 6.7 6 0.9 (n 5 6)i
IL-1b/DAH (2 h) 31.7 6 2.8 (n 5 6)¶ 5.5 6 0.7 (n 5 6)¶ 3.6 6 0.5 (n 5 6)¶
IL-1b (24 h) 49.5 6 4.7 (n 5 6)¶ 2.0 6 0.6 (n 5 6)¶ 1.4 6 0.3 (n 5 6)¶
Mice received either saline (0.25 ml intraperitoneally). IL-1b (5 ng intraperitoneally), or IL-1b/des-arg10HOE 140 (DAH, 2.5 nmol
intraperitoneally). Data are mean 6 SEM for animals.
*Rolling velocity.
‡No. of cells per 100 mm vessel length.
§No. of cells per 100 3 50 mm2.
iP , 0.05 versus saline-treated values.
¶P , 0.05 versus IL-1b–treated (2 h) values.370 Kinin B1 Receptor Expression and Leukocyte Trafficking
1:20,000) overnight at 48C. After six washes with PBS-T, blots
were incubated 2 h with a 1:5,000 dilution of a peroxidase-cou-
pled donkey anti–rabbit antibody, followed by six washes with
PBS-T. Visualization of the antibody–protein complex was
achieved using an ECL detection reagent (ECL kit; Amersham
Pharmacia Biotech) followed by exposure to scientific imaging
film (Kodak) for 1–5 min. Full-range molecular weight markers
were from Amersham Pharmacia Biotech. In preadsorption ex-
periments, the antibody was incubated with its corresponding
peptide at a concentration of 10 mg/ml at 48C overnight.
Mechanisms of the Cellular Response to DABK. To confirm
that the effect of DABK was via the activation of B1 receptors,
24 h after sensitization of the mice with IL-1b (5 ng), DABK (30
nmol) was coinjected with either the B1 receptor antagonist des-
arg10HOE 140 (25 nmol intraperitoneally) or the chemically
related selective B2 receptor antagonist HOE 140 (d-Arg-
[Hyp3,Thi5,d-Tic7,Oic8]-BK (25 nmol intraperitoneally; gift
from Hoechst, Frankfurt, Germany). These doses were chosen
from preliminary observations (not shown). The mesenteric vas-
cular bed was visualized, and the neutrophil response was assessed
2 h later.
To determine whether the effects of the B1 receptor agonist
involved activation of sensory C fibers, mice were pretreated
with a single subcutaneous injection of capsaicin (50 mg/kg;
Sigma-Aldrich) 4 d before the administration of IL-1b. This cap-
saicin treatment produces .90% depletion of sensory neuropep-
tide content in mice (21).
To ascertain the involvement of specific neuropeptide recep-
tors, histamine H1 receptors, platelet activating factor (PAF), and/
or mast cells, either the calcitonin gene-related peptide (CGRP)
antagonist, CGRP-(8–37) (300 nmol/kg intravenously, 15 min
[22]; Bachem); the neurokinin (NK)1 receptor antagonist SR
140333, (S)1-(2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphen-
ylacetyl)pip eridin-3- yl]ethyl)-4-phenyl-1-azoniabicyclo[2.2.2]
octane chloride (0.1 mmol/kg intravenously, 30 min [23]); the
NK2 receptor antagonist MEN 11420, (cyclo [Asn(b-d-GlcNAc)-
Asp-Trp-Phe-Dap-Leu]cyclo [2b-5b]) (0.1 mmol/kg intrave-
nous 15-min pretreatment [24]); the NK3 receptor antagonist SR
142801, (S)-(N)-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperi-
din-3-yl)-propyl)-4-phenylepipiperidin-4-y)-N-methylacetamide
(4 mmol/kg intravenously for 15 min [25]) (all gifts from Dr.
C.A. Maggi, synthesized in the Chemistry Department of Me-
narini Research, Florence, Italy); the H1 receptor antagonist
triprolidine (1 mg/kg intraperitoneally, 20 min [26]; Sigma-
Aldrich), the PAF antagonist WEB 2086 (26), 3-[4-(2-chlorphe-
nyl)-9-methyl-6H-thienol[3,2-f][1,2,4]tria-zolo-[4,3-a] [1,4]-diaz-
epine-2-yl]-1-(morpholinyl)-1-propanon (5 mg/kg intravenously,
20 min [27]; Boheringer); or the mast cell degranulating agent
compound 48/80 (1.2 mg/kg intraperitoneally, 72 h [28, 29];
Sigma-Aldrich) were administered before DABK, and the neu-
trophil response was assessed at the 2-h time point.
In other experiments, substance P (7.5 nmol intraperitoneally),
compound 48/80 (1.2 mg/kg intraperitoneally), or PAF (1 mg,
intraperitoneally) were administered, and the neutrophil response
assessed at the 1- or 2-h time point. In control experiments, sub-
stance P  was tested against SR 140333, MEN 11420, or SR
142801, with compound 48/80 against triprolidine and PAF
against WEB 2086 in the doses specified above.
Kinin B2 Receptor Knockout Mice. B2 receptor knockout mice
(BK2r2/2) were produced by homologous recombination in em-
bryonic stem cells and generated on a mixed background of J129 3
C57 as described previously (30; gift from Merck Research Labo-
ratories, Terlings Park, UK). Wild-type mice derived from the
same background were used as controls. Animals were bred and
housed in specific pathogen-free facilities and used when their
weight was between 11 and 16 g. The effect of DABK (30 nmol
intraperitoneally) and saline was tested in BK2r2/2 mice 24 h af-
Figure 1. Videomicroscopy images of leukocyte trafficking responses
in mouse mesenteric postcapillary venules in vivo in response to (A) saline
(0.25 ml intraperitoneally, 2 h), (B) IL-1b (5 ng intraperitoneally, 2 h),
and (C) IL-1b (5 ng intraperitoneally, 24 h).371 McLean et al.
ter IL-1b treatment (5 ng intraperitoneally), and the cellular re-
sponse compared with that observed in the wild-type BK2r1/1
animals, following the protocols detailed above.
Data Analysis. All values in the figures and text are expressed
as mean 6 SEM of n observations, where n represents the num-
ber of animals studied. Data sets were examined by one- and
two-way analysis of variance, and individual group means were
compared with Student’s unpaired t test. A P value ,0.05 was
considered significant.
Results
Leukocyte–Endothelial Cell Interactions in Postcapillary
Venules of the Mouse Mesentery. In control animals injected
with saline, leukocytes rolled in vivo on the endothelium at
high speed (VWBC 5 54.9 6 6.9 mm/sec, n 5 11). In con-
trast, cells moved significantly (P  ,  0.05) more slowly
(VWBC 5 9.1 6 2.1 mm/sec, n 5 7) 2 h after intraperito-
neal administration of IL-1b (5 ng). This reduction in
VWBC was accompanied by a significant increase in cell ad-
hesion and emigration (Table I and Fig. 1). Treatment with
the B1 receptor antagonist des-arg10HOE 140 (25 nmol/
mouse intraperitoneally) significantly (P , 0.05) reduced
IL-1b–induced leukocyte rolling, adhesion, and emigration
at 2 h (Table I). By 24 h, the inflammatory response to IL-
1b, as assessed by the cellular response, had subsided (Table
I and Fig. 1).
Characterization of DABK-induced Leukocyte Recruitment.
To investigate the effects of B1 receptor activation on leu-
kocyte–endothelial cell interactions in vivo, microscopic
visualization of postcapillary venules was performed after
the administration of the B1 receptor agonist DABK. 24 h
after challenge with IL-1b, DABK but not saline triggered
intense leukocyte rolling, adhesion, and emigration at 2
and 4 h (Fig. 2). These effects of DABK were only seen in
animals pretreated with IL-1b, and not in those pretreated
with saline or the chemokine IL-8 (Fig. 2; see Fig. 4). The
vast majority of cells infiltrating the subendothelial matrix
were neutrophils, as demonstrated by histological analysis
(Fig. 3). Further analysis revealed that in mesenteries from
animals treated with DABK (2 h), 71.0 6 6.7% of mast
cells had degranulated (Fig. 3; n 5 3). In contrast, only 4.3 6
1.5% (P , 0.05) were degranulated in control (saline-
treated, 2 h) animals (n 5 3). No significant change in total
mast cell number was observed between groups (control,
2.03 6 0.03 3 103 cells/mm2; DABK treated, 1.77 6 0.12 3
103 cells/mm2; P . 0.05).
DABK-induced leukocyte recruitment was a time- (Fig.
2) and dose-dependent (Fig. 4) process. A maximal de-
crease in VWBC (48% reduction from basal) was observed 2 h
after DABK treatment. This led to a 200% increase in cell
adhesion at 2 h, which increased further to 280% at 4 h.
The number of emigrated leukocytes increased by 65% at 2 h
and 171% at 4 h after DABK (Fig. 2).
There was no difference in RBC (centerline) velocity,
venule diameter, and shear rate for any of the experimental
groups. An apparent reduction in shear rate was seen in the
IL-1b (24 h)/DABK (4 h) group; however this did not
reach statistical significance compared with the IL-1b (24 h)/
saline (4 h) group (Table II).
Molecular Expression of B1 Receptor mRNA After IL-1b
Treatment. RT-PCR of mesenteric mRNA from saline-
treated mice revealed minimal expression of B1 receptor
mRNA. In contrast, a marked increase in expression was
consistently detected in mesenteries taken from mice 24 h
after IL-1b treatment (Fig. 5 A; n 5 3). A similar pattern of
B1 receptor mRNA induction was observed in mesenteries
from BK2r2/2 mice (Fig. 5 A; n 5 3). GAPDH mRNA
was detected in all mesenteries tested, the level of which
was consistent within strains. Fig. 5 (inset) shows that the
PCR analyses of both the B1 receptor and GAPDH genes
were amplified over several cycles that gave rise to a linear
relationship between starting amount of cDNA and prod-
uct intensity.
Induction of B1 Receptor Protein by IL-1b Treatment.
Western blot analysis of mesenteric tissue protein collected
from IL-1b–pretreated mice showed a band with an appar-
ent molecular mass of z39 kD (Fig. 5 B; n 5 4) corre-
sponding to the mouse B1 receptor (19). This band was not
observed when tissue from saline-treated mice was used (n 5
4). The specificity of the response of the A15C antibody
was further demonstrated by the ability of the free A15C
peptide (20) to inhibit the presence of this band (Fig. 5 B).
Receptor Specificity of DABK-induced Leukocyte Trafficking.
The effects of DABK on leukocyte recruitment were sig-
nificantly attenuated by the concomitant administration of
Figure 2. Leukocyte–endothelial cell in-
teractions in mouse mesenteric postcapillary
venules in vivo in response to B1 receptor
activation with DABK (30 nmol intraperi-
toneally). (A) Leukocyte rolling velocity,
(B) leukocyte adhesion, and (C) leukocyte
emigration were examined 2 and 4 h after
DABK or saline administration. Mice re-
ceived either DABK (d) or saline (j) 24 h
after IL-1b (time 5 0). The effect of DABK
in saline- (s, 24 h) or IL-8–treated (h, 24 h)
mice is also shown. Data are mean 6 SEM
for n 5 5–8 animals per group. *P , 0.05
versus saline-treated values.372 Kinin B1 Receptor Expression and Leukocyte Trafficking
Figure 3. Identification of leukocytes by (A and B) hema-
toxylin and eosin staining and (C and D) mast cells by tolui-
dine blue staining of mesenteries from mice treated with either
(A, B, and D) DABK (2 h) 24 h after IL-b or (C) saline (2 h).
(A) Mesenteric section showing a postcapillary venule (v) and
arteriole (a); original magnification: 320. (B) Postcapillary venule (v) with a predominance of polymorphonuclear cells (arrowheads) either attached
within or emigrated from the venule (original magnification: 3100). (C) Nondegranulated mast cells (arrowheads) in saline-treated mice (original magni-
fication: 340; inset original magnification: 3100). (D) Degranulated mast cells (arrowheads) in DABK/IL-1–treated mice (original magnification: 340;
inset original magnification: 3100).373 McLean et al.
the B1 receptor selective antagonist des-arg10HOE 140 (25
nmol, n 5 6; Fig. 6), whereas HOE 140 (25 nmol, n 5 6;
Fig. 6) had no effect.
Mechanisms of the Enhanced Leukocyte–Endothelial Cell In-
teractions Induced by B1 Receptor Activation. Systemic treat-
ment with capsaicin (n 5 6) significantly reduced DABK-
induced effects on leukocyte accumulation, producing a
similar level of inhibition on rolling, adhesion, and emigra-
tion (Fig. 7). Treatment with SR 140333 (n 5 6) produced
a similar extent of inhibition to that observed with capsai-
cin (Fig. 7). Neither MEN 11420 (n 5 5), CGRP-(8–37)
(n 5 5), nor WEB 2086 (n 5 4) had any significant effect
on the response to DABK (Fig. 7). SR 142801 (n 5 4),
compound 48/80 (n 5 6), and triprolidine (n 5 4) signifi-
cantly (P , 0.05) inhibited leukocyte rolling and cell adhe-
sion (Fig. 7), but to a lesser extent than was observed with
SR 140333 or capsaicin (Fig. 7).
Leukocyte–Endothelial Cell Interactions in Response to Sub-
stance P. 24 h after challenge with IL-1b, substance P (7.5
nmol) promoted leukocyte recruitment from mesenteric
postcapillary venules, with VWBC, cell adhesion, and emi-
gration all being affected (Fig. 8). This response to sub-
stance P was significantly reduced by treatment with SR
140333 (n 5 4; Fig. 8). In contrast, MEN 11420 (0.1
mmol/kg, n 5 4) had no significant effect on the response
to substance P (Fig. 8). SR 142801 (4 mmol/kg, n 5 4) also
inhibited substance P–induced effects; however, this inhi-
bition was not as marked as that achieved with SR 140333
(Fig. 8).
Leukocyte–Endothelial Cell Interactions in Response to Com-
pound 48/80 and PAF. Acute administration of com-
pound 48/80 (1.2 mg/kg intraperitoneally, 1 h) produced
an inflammatory response characterized by slow leukocyte
rolling, adhesion, and emigration (Fig. 8). These effects
were significantly reduced by pretreatment with the H1 re-
ceptor antagonist triprolidine (n 5 4; Fig. 8). Histological
assessment showed that 93 6 7% (n 5 3) of mesenteric
mast cells had degranulated after compound 48/80 treat-
ment.
PAF (1 mg) promoted leukocyte recruitment from me-
senteric postcapillary venules, with VWBC, cell adhesion,
and emigration all being affected (Fig. 8). This response to
PAF was abolished by treatment with WEB 2086 (n 5 4;
Fig. 8).
Leukocyte–Endothelial Cell Interactions in BK2r2/2 Mice.
Neither DABK (30 nmol intraperitoneally) nor saline
treatment 24 h after IL-1b treatment (5 ng intraperito-
neally) revealed any significant difference in leukocyte–
endothelial cell interactions between the wild-type (BK2r1/1)
and knockout (BK2r2/2) mice (Fig. 9). An apparent 23%
reduction of DABK-induced cell emigration was observed
in BK2r2/2 relative to wild-type mice; however, this did
not reach statistical significance (P 5 0.13, n 5 6). Neither
DABK nor saline treatment 24 h after IL-1b treatment
produced any significant effect on RBC (centerline) veloc-
ity, venule diameter, or shear rate in either genotype (Ta-
ble III).
Discussion
This study describes, for the first time, a functional role
for the B1 receptor in the processes regulating the initial
steps of leukocyte extravasation in experimental inflamma-
tion. We have demonstrated that B1 receptor activation
with DABK, 24 h after treatment with the cytokine IL-1b
but not after treatment with saline or IL-8, triggers leuko-
cyte rolling on and adhesion to the endothelium and emi-
gration from mouse mesenteric postcapillary venules. Addi-
tionally, these responses were temporally associated with de
novo B1 receptor mRNA and protein expression. Further-
more, we have shown that the induction of the receptor
and reactivity to DABK are not affected in BK2r2/2 mice.
Figure 4. DABK causes dose-related changes in (A) leukocyte rolling
velocity, (B) adhesion, and (C) emigration in mouse mesenteric postcapil-
lary venules. Mice received DABK (10–30 nmol in 0.25 ml saline, intra-
peritoneally) 24 h after IL-1b (d; 5 ng in 0.25 ml saline intraperitoneally)
or saline alone (s; 0.25 ml intraperitoneally). Leukocyte responses were
examined 2 h after DABK treatment. Data are mean 6 SEM for n 5 5–8
animals per group. *P , 0.05 versus saline-treated values.374 Kinin B1 Receptor Expression and Leukocyte Trafficking
We have also characterized the mechanisms involved,
identifying substance P (probably released from sensory C
fibers) and mast cell degranulation as mechanisms involved
in mediating the DABK-induced cellular response.
IL-1b is a proinflammatory cytokine that plays an integral
role in the initiation of leukocyte–endothelial cell interac-
tions during an inflammatory response (14, 31). Application
of IL-1b causes leukocyte recruitment across mouse mesen-
teric postcapillary venules similar to that seen within the rat
mesenteric microcirculation (14, 15). This response to IL-
1b involves induction and activation of B1 receptors, as
coadministration of the selective B1 receptor antagonist des-
arg10HOE 140 reduced IL-1b–induced leukocyte rolling,
adhesion, and emigration from postcapillary venules. The
extent of inhibition obtained (z50%) is in line with that
observed in gross models of neutrophil extravasation (7).
The association between B1 receptor activation and leu-
kocyte trafficking was studied using the B1 receptor selec-
tive agonist DABK. The 24-h time point after IL-1b was
chosen because the cellular response to the cytokine itself
had subsided. DABK produced a dose- and time-dependent
sequential response characterized by leukocyte rolling fol-
lowed by adhesion and then emigration. Histochemical
studies confirmed that .90% of the leukocytes involved in
Table II. Hemodynamic Parameters of Venules Studied
Treatment (time) No. of venules Venule diameter Centerline velocity
Calculated wall 
shear rate
mm mm/s s21
Saline (2 h) 18 27.9 6 2.1 1.5 6 0.1 287 6 22 
IL-1b (2 h) 10 29.2 6 2.2 1.3 6 0.1 235 6 24
IL-1b/DAH (2 h) 18 26.8 6 0.9 1.4 6 0.1 269 6 17 
IL-1b (24 h)/saline (2 h) 11 29.6 6 1.7 1.5 6 0.1 265 6 21 
IL-1b (24 h)/saline (4 h) 6 25.6 6 1.3 1.4 6 0.1 270 6 32
IL-1b (24 h)/DABK (2 h) 9 33.5 6 2.9 1.7 6 0.3 253 6 32
IL-1b (24 h)/DABK (4 h) 9 24.0 6 1.4 1.5 6 0.1 208 6 13
Mice received either saline (0.25 ml), IL-1b (5 ng intraperitoneally), IL-1b (5 ng)/des-arg10HOE 140 (DAH; 25 nmol intraperitoneally), or IL-1b
(5 ng intraperitoneally, 24 h) followed by DABK (2 or 4 h). Data are mean 6 SEM.
Figure 5. Upregulation of the B1 recep-
tor by IL-1b in mouse mesenteric vascular
bed. (A) Detection of B1 receptor mRNA
by RT-PCR. B1 receptor (435 bp) and
GAPDH (363 bp) PCR products amplified
from polyA1 RNA extracted from mesen-
teric vascular beds from either saline- (0.25
ml, intraperitoneally) or IL-1b–treated (5
ng in 0.25 ml saline, intraperitoneally) mice.
Positive PCR control is a mouse B1 recep-
tor cDNA plasmid. Results are representa-
tive of tissue from at least three animals per
group. Inset: PCR product yield as a func-
tion of initial amount of cDNA. Serial dilutions of cDNA be-
fore PCR results in a log plot in which a linear relationship
between starting amount of cDNA and product intensity is
observed. B1 receptor and GAPDH curves are parallel (P .
0.05). (B) Western blot analysis of the expression of mouse B1
receptor using the IgG purified from A15C (reference 27; di-
lution 1:20,000) on mesenteric tissues (20 mg protein per
lane). Mesenteric tissue were taken from either saline- (0.25
ml intraperitoneally) or IL-1b–treated (5 ng in 0.25 ml saline
intraperitoneally) mice. Results are representative of tissue
from four experiments. 1 anti B1 represents inhibition of de-
tection of the 39-kD band when the antibody is preincubated
(overnight at 48C) with the A15C peptide at a concentration
of 10 mg/ml. Molecular mass marker proteins were run si-
multaneously. Their molecular masses (kD) are shown on the
left side of the figure.375 McLean et al.
this response were neutrophils. The time dependency of
these phenomena suggests a sequential process in which
each step is a prerequisite for the next, as observed for other
inflammatory stimuli in the same vascular bed (16). Impor-
tantly, DABK had no effect in animals treated with saline or
previously inflamed with the chemokine IL-8. Together,
these data show that in the mouse mesenteric microcircula-
tion, functional B1 receptors are not constitutively expressed
but are induced selectively by the cytokine IL-1b.
The functional response to the B1 receptor agonist corre-
lated with induction of the receptor. IL-1b has been shown
to be an optimal inducer of B1 receptor expression on sev-
eral cell types in vitro (32, 33). This includes human em-
bryo lung fibroblasts where IL-1b upregulates B1 receptor
mRNA expression at both a transcriptional and posttran-
scriptional level (20, 34). However, no study to date has
shown an ability of this cytokine to induce B1 receptor
mRNA and protein expression in vivo. In this study, IL-
1b treatment caused an upregulation of B1 receptor
mRNA expression, leading to de novo protein synthesis. A
modest basal expression of the B1 receptor mRNA was
seen in saline-injected animals. However, this was not asso-
ciated with detectable expression of the protein. These re-
sults suggest that although low-level expression of B1 re-
ceptor mRNA is constitutively expressed in the mesenteric
microvasculature, an appropriate inflammatory stimulus is
required to achieve optimal transcription and translation.
Figure 6. The effect of B1 or B2 receptor blockade on the changes in
leukocyte kinetics induced by DABK (30 nmol). Mice were injected with
IL-1b (5 ng) 24 h before DABK together with saline, des-arg10HOE 140
(DAHOE 140; B1 receptor antagonist, 25 nmol) or HOE 140 (B2 recep-
tor antagonist, 25 nmol). Leukocyte kinetics (A) rolling velocity, (B) ad-
hesion, and (C) emigration were examined 2 h after DABK treatment.
Data are mean 6 SEM for n 5 5–8 animals per group. *P , 0.05 versus
saline-treated values.
Figure 7. Effect of capsaicin, compound 48/80, and a range of selec-
tive receptor antagonists on DABK-induced (30 nmol intraperitoneally)
changes in (A) leukocyte rolling velocity, (B) leukocyte adhesion, and (C)
leukocyte emigration at the 2-h time point. Values from saline-treated
control animals were VWBC 5 52.8 6 6.6 mm/s; adherent leukocytes 5
1.9 6 0.5 cells/100 mm; emigrated leukocytes 5 0.2 6 0.1 cells/100 3
50 mm2. The following specific treatments were used: capsaicin (50 mg/
kg subcutaneously, 4 d); CGRP-(8–37) (300 nmol/kg intravenously, 15
min); SR 140333 (0.1 mmol/kg intravenously, 30 min); MEN 11420 (0.1
mmol/kg intravenously, 15 min); SR 142801 (4 mmol/kg intravenously,
15 min); WEB 2086 (5 mg/kg intravenously, 20 min); compound 48/80
(1.2 mg/kg intraperitoneally, 72 h [reference 23]); and triprolidine (1 mg/
kg intraperitoneally, 20 min [reference 26]). Data are mean 6 SEM for
n 5 6 animals per group. *P , 0.05 versus DABK-treated values.376 Kinin B1 Receptor Expression and Leukocyte Trafficking
The molecular studies were supported by the functional
data. DABK-induced leukocyte rolling, adhesion, and emi-
gration was mediated by B1 receptors, as the selective B1
receptor antagonist des-arg10HOE 140 almost abolished the
effects of the agonist (90–95% reduction), whereas the
chemically related B2 receptor selective antagonist HOE
140 was without effect. This cellular response was not due
to a nonspecific alteration in local hemodynamics, as no
significant change in blood flow or shear rate was observed.
The lack of involvement of B2 receptors in DABK re-
sponses was confirmed by the experiments performed with
the BK2r2/2 mice. Quantitatively equal responses to
DABK were achieved in BK2r1/1 mice and BK2r2/2
mice. Taken together, these data show that IL-1b induces
expression of functional B1 receptors in a manner indepen-
dent of B2 receptor expression.
We next studied the mechanism(s) by which B1 receptor
activation causes leukocyte recruitment. Other studies have
proposed that DABK-induced neutrophil accumulation is
mediated indirectly, as DABK does not directly modify
neutrophil function in vitro (7), whereas neuropeptide re-
ceptor antagonists (7) block neutrophil accumulation in
gross models of experimental inflammation in vivo (8). We
hypothesized that the DABK-induced rolling, adhesion,
and emigration may be mediated by the release of neu-
ropeptides from sensory C fibers. Therefore we investi-
gated the effects of C fiber desensitization with capsaicin
using a validated protocol providing .90% depletion of
sensory neuropeptide content (21). Using this protocol,
DABK-induced leukocyte rolling, adhesion, and emigra-
tion were attenuated by 73, 91, and 71%, respectively.
Therefore, activation of C fibers is pivotal in mediation of
B1 receptor–induced leukocyte recruitment.
Figure 8. Effect of a range of selective receptor antagonists on sub-
stance P– (7.5 nmol intraperitoneally), compound 48/80– (1.2 mg/kg in-
traperitoneally), and PAF-induced (1 mg intraperitoneally) changes in (A)
leukocyte rolling velocity, (B) leukocyte adhesion, and (C) leukocyte em-
igration at the 2-h time point. Values from saline-treated control animals
are VWBC 5 58.7 6 9.2 mm/s; adherent leukocytes 5 1.0 6 0.5cells/100
mm; emigrated leukocytes 5 0.7 6 0.1 cells/100 3 50 mm2). The fol-
lowing specific treatments were used: SR 140333 (0.1 mmol/kg intrave-
nously, 30 min); MEN 11420 (0.1 mmol/kg intravenously, 15 min); SR
142801 (4 mmol/kg intravenously, 15 min); triprolidine (1 mg/kg intra-
peritoneally, 20 min); and WEB 2086 (5 mg/kg intravenously, 20 min).
Data are mean 6 SEM for n 5 6 animals per group. *P , 0.05 versus
substance P–, compound 48/80–, or PAF-treated values.
Figure 9. Leukocyte kinetics. (A) rolling velocity, (B) adhesion, and
(C) emigration in the mesenteric vascular bed of BK2r2/2 (white bars)
and BK2r1/1 (black bars) mice. Mice were injected with IL-1b (5 ng in-
traperitoneally) 24 h before DABK (30 nmol intraperitoneally). No sig-
nificant difference (P . 0.05) in any of the parameters measured was ob-
served in BK2r2/2 compared with BK2r1/1 mice 2 h after DABK
treatment. Data are mean 6 SEM for n 5 5–8 animals per group. *P ,
0.05 versus saline-treated values within the same genetic background.377 McLean et al.
A substantial body of evidence suggests an important role
of proinflammatory neuropeptides, such as substance P and
CGRP, in C fiber–mediated neurogenic inflammation (35,
36). Neuropeptides produce their effects via the selective
activation of G protein–coupled receptors. Three neurokinin
receptors—NK1, NK2, and NK3—have been characterized
based on the relative order of potency of their correspond-
ing endogenous agonists: substance P, neurokinin-A, and
neurokinin-B, respectively (37). To identify the neuropep-
tide(s) involved in the B1 receptor–mediated leukocyte–
endothelial cell interaction, we used a range of selective
antagonists with established selectivity for neuropeptide
receptors (38). Blockade of NK1 receptors with the selec-
tive antagonist SR 140333 produced an inhibition (rolling,
adhesion, and emigration reduced by 60, 82, and 60%, re-
spectively) similar to that observed with capsaicin. The
dose of SR 140333 used in this study was previously vali-
dated for selectivity at NK1 receptors (23). The order of
potency for neurokinins at their receptors (39) would sug-
gest that the B1 receptor–mediated enhancement of leuko-
cyte–endothelial cell interactions is mediated predomi-
nantly by substance P. This possibility is further confirmed
by the lack of activity of the selective NK2 receptor antago-
nist MEN 11420. A partial role for NK3 receptors in the
response may be possible, as blockade with the NK3 recep-
tor antagonist, SR 142801, reduced DABK-induced roll-
ing, adhesion, and emigration by 33, 64, and 50%, respec-
tively. NK-B, the preferred endogenous agonist for the
NK3 receptor, is not expressed to any appreciable extent in
the periphery (37). However, it is of interest to note that
functional NK3 receptors have been shown to be present in
mesenteric vascular venous beds (40). It is therefore possi-
ble that during inflammation, these receptors might be acti-
vated by substance P. This was confirmed by the observa-
tion that substance P–induced leukocyte rolling, adhesion,
and emigration were also reduced by SR 140333 and SR
142801. The lack of activity of the selective CGRP recep-
tor antagonist, CGRP-(8–37), precludes an involvement of
this neuropeptide in the observed response.
A recent study has illustrated the ability of a relatively
high dose of BK to cause B2 receptor–mediated leukocyte
recruitment in rat mesentery postcapillary venules (41).
This response was shown to be mediated by PAF release,
possibly from the endothelium or macrophages (41). How-
ever, this high-dose BK treatment was accompanied by a
significant reduction in shear rate, which may have been a
contributory factor in the leukocyte response observed. In
contrast, in this study, no change in shear rate was observed
after DABK treatment. Furthermore, the PAF antagonist
WEB 2086 had no effect on the response to DABK,
whereas it abolished the response to PAF itself. These data
imply that distinct mechanisms exist for kinin receptor–
mediated leukocyte recruitment, with B1 receptors acting
predominantly via the release of neuropeptides, and B2 re-
ceptors activating PAF release (41).
Mast cells play an important role in the initiation and
progression of the inflammatory response (42). Of particu-
lar relevance is their role in cellular accumulation (42), and
also their role in neurogenic inflammation via a close rela-
tionship and interaction with sensory C fibers (43). Indeed,
it has been demonstrated that C fibers and mast cells are of-
ten in intimate proximity (44) and share biochemical and
functional cooperativity (45, 46–49). Therefore, we inves-
tigated the involvement of mast cells in the DABK-induced
leukocyte recruitment response by depleting (.80%) peri-
toneal mast cells with the selective serosal mast cell degran-
ulator, compound 48/80, using a well-established protocol
(28, 29). The efficacy of this protocol was confirmed histo-
logically and by the demonstration that acute administra-
tion of compound 48/80 itself induces leukocyte recruit-
ment. This effect of compound 48/80 is most likely due to
degranulation of mast cells, as pretreatment of mice with
the H1 receptor triprolidine attenuated the response by 70–
80%. Compound 48/80 is known to be inactive on neutro-
phil and/or endothelial cells, but it can promote leukocyte–
endothelial cell interactions in vitro only when cocultured
with mast cells (42). Mast cell depletion with compound
48/80 significantly attenuated the response to DABK, sug-
gesting that mast cells play an important role in media-
tion of this response. Further support for an involvement
of mast cells in the DABK-induced response was pro-
vided by histological studies demonstrating intense mast
cell degranulation after DABK treatment. Additionally, as
with the acute response to compound 48/80, the DABK-
Table III. Hemodynamic Parameters of Venules Studied: BK2r2/2 Mice
Mouse genotype (treatment) No. of venules Venule diameter Centerline velocity
Calculated wall 
shear rate
mm mm/s s21
Wild-type (saline) 11 28.0 6 2.1 1.7 6 0.1 318.0 6 47.1
BK2r2/2 (saline) 7 28.7 6 1.9 1.5 6 0.1 257.0 6 19.1
Wild-type (IL-1b/DABK) 13 26.9 6 1.6 1.4 6 0.1 273.7 6 25.2
BK2r2/2 (IL-1b/DABK) 25 30.0 6 0.8 1.4 6 0.1 239.1 6 9.5
Mice received either saline (0.25 ml intraperitoneally) or IL-1b (5 ng intraperitoneally, 24 h) followed by DABK (2 h). Data are mean 6 SEM.378 Kinin B1 Receptor Expression and Leukocyte Trafficking
induced response was suppressed by the H1 receptor antag-
onist supporting a role for histamine. PAF is unlikely to be
involved, as the response was not affected by the PAF an-
tagonist WEB 2086 (27). Thus it is clear that both C fibers
and mast cells are involved in mediating the B1 receptor–
induced leukocyte trafficking. The exact relationship and
sequence of events between the C fiber– and mast cell–
dependent pathways is less clear. It is possible that DABK
causes substance P  release, which in turn activates mast
cells, as this neuropeptide is known to do (46, 47, 50, 51),
thereby stimulating the process of neutrophil extravasation
(49). Conversely, DABK may also activate mast cells, re-
sulting in the release of mediators such as histamine, seroto-
nin, or mast cell tryptase, which are known to activate the
release of neuropeptides from C fibers (45, 52, 47, 53).
Further studies are required to determine the precise cellu-
lar location of the kinin B1 receptor. However the evi-
dence presented in this study suggests that the receptor may
be expressed on C fibers and/or mast cells.
The molecular mechanisms of substance P– and hista-
mine-induced leukocyte trafficking are known to involve
the specific upregulation and rapid mobilization of certain
adhesion molecules for PMNs; e.g., substance P causes the
upregulation and mobilization of P-selectin, intercellular
adhesion molecule (ICAM)-1, vascular cell adhesion mole-
cule (VCAM)-1, and endothelial leukocyte adhesion mole-
cule (ELAM)-1 (54–57), and histamine-induced leukocyte
recruitment is known to be mediated in part by P-selectin
(55–57, 58). Given our findings implicating substance P
and histamine in the response to DABK, it is likely that
DABK-induced leukocyte trafficking involves similar mech-
anisms. However, confirmation of this will be the subject
of further study.
Conclusion. To summarize, we have shown that IL-1b
treatment induces the de novo expression of functional B1
receptors in the mouse mesentery. Activation of these re-
ceptors induces interactions between circulating leukocytes
and the venular endothelium, leading to leukocyte emigra-
tion from postcapillary venules. The B1 receptor–mediated
cellular response is dependent on activation of both C fi-
bers and mast cells, the effects of which are mediated by
tachykinin NK1, NK3, and histamine H1 receptor activa-
tion. In conclusion, we propose that inhibition of early
leukocyte–endothelial cell interactions leading to reduced
neutrophil recruitment represents an important additional
mechanism for the antiinflammatory effects provided by B1
receptor antagonism. B1 receptors may be involved in cer-
tain inflammatory pathologies such as inflammatory hyper-
algesia (4, 59) and endotoxic shock (60), and have been
implicated in atheromatous disease (61) and myocardial
ischemia (62). Thus, the B1 receptor is clearly a target for
the development of novel antiinflammatory drugs with a
potent action on the events that lead to leukocyte recruit-
ment.
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